About S3V Vascular Technologies Limited
Founded in 2011 and headquartered in the industrial hub of Mysore, Karnataka, S3V Vascular Technologies Limited has emerged as a formidable force in the high-end medical device manufacturing sector.
Specializing in cardiovascular and neurovascular interventions, S3V is not just a manufacturer; it is a national asset reducing India’s reliance on expensive imports.
In a historic milestone, S3V became the first company globally to receive a manufacturing license for an expandable titanium-based Intervertebral Body Fusion Device (Expandable Spinal Cage). The successful placement of the first such spinal implant in Pune marked India’s entry into elite spinal surgery technology—a space where S3V remains the only manufacturer in the world for this specific cage .
2. Business Model: Fully Integrated R&D to Manufacturing
Unlike many Indian medical device companies that focus solely on assembly or distribution, S3V follows a fully integrated business model. By combining in-house R&D, proprietary technology development, and regulated manufacturing facilities, the company retains complete control over quality and cost.
S3V caters to both Indian and global markets through:
This model allows the company to produce high-quality, life-saving devices that are significantly more affordable than their imported counterparts, directly addressing the affordability crisis in Indian healthcare.
3. Product Portfolio: Beyond Stents
While S3V is renowned for high-end interventional products, its portfolio is a testament to its engineering prowess:
-
Cardiac Solutions: Drug-Eluting Stents (DES), Bare-Metal Stents, PTCA Catheters, and the newly unveiled Balloon-Expandable TAVR system (Transcatheter Aortic Valve Replacement) .
-
Gastrointestinal: Esophageal and Biliary Stents.
-
Neurovascular: India’s first indigenous Mechanical Thrombectomy Device (for treating brain strokes), Microcatheters, Aspiration Catheters, and Stent Retrievers .
-
Spine: The world’s only expandable Titanium Spinal Cage.
Latest Breakthrough: The Indigenous TAVR System (March 2026)
In a move set to democratize cardiac care, S3V recently unveiled its “Made in India” Transcatheter Aortic Valve Replacement (TAVR) system.
-
The Problem: Imported TAVR valves cost between ₹13 lakh and ₹23 lakh, leaving 46,000 out of 50,000 patients who need the surgery unable to afford it .
-
The Solution: S3V’s domestically engineered valve aims to cut costs dramatically while providing a minimally invasive alternative to open-heart surgery. The device has entered preclinical evaluation with commercial launch expected within 12-18 months .
4. Market Opportunity: Tapping the $2 Billion Neuro Market
India is witnessing an epidemic of cardiovascular and neurovascular diseases. The neuro-intervention market alone is a $2 billion segment, yet it is dominated by Western imports .
S3V is strategically positioned to fill this gap. With regulatory compliance including ISO-13485 and ongoing CE and USFDA approval processes, the company is targeting not just India but emerging markets across Asia, Latin America, and Europe .
5. Leadership: A Legacy of Innovation
The strength of S3V lies in its visionary leadership:
Mr. Badari Narayan (Promoter): A veteran with over 30 years of experience, Mr. Narayan holds an M. Pharmacy and a PGPMAX from ISB. He famously worked under Dr. A.P.J. Abdul Kalam to develop India’s lowest-cost cardiac stents. His career includes pioneering breakthroughs like the 316LVM stents (1999) and Sirolimus DES (2006).
Second-Generation Leadership:
-
Dr. Vijaya Gopal (MBBS): Heading R&D, driving the neurovascular and TAVR innovation.
-
Vishnu Shreyas N.G. (Engineer): Heading Operations.
Having the second generation actively involved for the last five years ensures continuity and fresh energy in the business .
6. Strategic Capital Raise & Valuation (2024-2025)
Investor confidence in S3V is exceptionally high. In March 2024, the company raised ₹110 crore at a pre-money valuation of ₹228 crore.
The Investors:
-
A.M. Naik (L&T Group Chairman Emeritus) & team: ₹35+ crore.
-
Madhusudan Kela & team: ₹25+ crore.
-
Utpal Sheth (Rare Enterprises) & Sumit Jalan (Credit Suisse).
Following the round, the post-money valuation stood at ₹338 crore (₹176/share). Fast forward to 2026, with market dynamics shifting, the unlisted market price has appreciated significantly, hovering in the range of ₹420 to ₹445 per share, reflecting a market cap of over ₹830 crore .
7. Government-Backed Expansion (2025-2026)
The Government of India has thrown its weight behind S3V via the Technology Development Board (TDB-DST) .
S3V is establishing a dedicated 12-acre Neuro Division facility at the Tamil Nadu Medical Devices Park (Oragadam, Chennai) to build the country’s first indigenous Mechanical Thrombectomy Kit .
-
Impact: This device is a game-changer for stroke treatment (Large Vessel Occlusion), offering the difference between “paralysis and recovery.”
-
Status: Prototype ready. Commercial production begins December 2025, with sales expected from Q4 FY26 and full market impact by FY27 .
8. Future Outlook: The Road to Global Leadership
S3V is currently executing a multi-pronged growth strategy:
-
Global Exports: Securing CE and USFDA approvals to take Indian innovation global.
-
Structural Heart: Launching the TAVR valve to capture the ₹400+ crore structural heart market.
-
Capacity Expansion: Scaling the Neurovascular manufacturing capacity to serve the $2 billion domestic market.
-
Affordability: Integrating with government schemes like Ayushman Bharat to make stroke care accessible to the masses .
9. S3V Vascular Technologies on Unlisted Network
As S3V Vascular Technologies is a Public Limited (Unlisted) company, its shares are not traded on the NSE or BSE. However, they are actively traded in the pre-IPO and unlisted market.
For investors looking to buy or sell shares of this high-growth MedTech innovator, Unlisted Network is the go-to platform. They provide a secure and transparent channel for trading unlisted shares, offering liquidity and price discovery for companies like S3V that are poised for explosive growth before their potential public listing.
Disclaimer
This content is for informational purposes only and does not constitute financial advice. Investments in the unlisted market involve risks; please consult your financial advisor before investing.
